癌症研究
阿扎胞苷
单克隆抗体
免疫疗法
低甲基化剂
免疫系统
抗原
CD3型
癸他滨
CD8型
免疫原性
免疫学
生物
医学
抗体
分子生物学
DNA甲基化
基因表达
生物化学
基因
作者
Alessia Covre,Sandra Coral,Hugues J. M. Nicolay,Giulia Parisi,Carolina Fazio,Francesca Colizzi,Elisabetta Fratta,Anna Maria Di Giacomo,Luca Sigalotti,P. G. Natali,Michele Maio
出处
期刊:OncoImmunology
[Landes Bioscience]
日期:2015-04-02
卷期号:4 (8): e1019978-e1019978
被引量:69
标识
DOI:10.1080/2162402x.2015.1019978
摘要
The multifaceted immunomodulatory activity of DNA hypomethylating agents improves immunogenicity and immune recognition of neoplastic cells; thus, we predicted they could be utilized to design new immunotherapeutic combinations in cancer. Testing this hypothesis, the antitumor efficacy of the DNA hypomethylating agent 5-aza-2'-deoxycytidine (5-AZA-CdR) combined with the anti-CTLA-4 monoclonal antibody (mAb) 9H10 in syngeneic transplantable murine models was investigated. Murine mammary carcinoma TS/A or mesothelioma AB1 cells were injected in BALB/c, athymic nude, and SCID/Beige mice that were treated with 5-AZA-CdR, mAb 9H10, or their combination. Tumor volumes were captured at different time-points; molecular and immunohistochemical assays investigated changes in neoplastic and normal tissues. A significant antitumor effect of 5-AZA-CdR combined with mAb 9H10 was found: compared to controls, a 77% (p < 0.01), 54% (p < 0.01) and 33% (p = 0.2) decrease in TS/A tumor growth was induced by 5-AZA-CdR combined with mAb 9H10, 5-AZA-CdR or mAb 9H10, respectively. These antitumor activities were confirmed utilizing the AB1 model. 5-AZA-CdR-based regimens induced a promoter-demethylation-sustained tumor expression of cancer testis antigens. MHC class I expression was up-regulated by 5-AZA-CdR. Antitumor efficacy of 5-AZA-CdR in athymic nude and SCID/Beige mice was not increased by mAb 9H10. In BALB/c mice, combined treatment induced the highest tumor infiltration by CD3+ lymphocytes, which included both CD8+ and CD4+ T cells; no such infiltrates were observed in normal tissues. This significant immune-related antitumor activity of 5-AZA-CdR combined with CTLA-4 blockade, demonstrated in highly aggressive mouse tumor models, provides a strong scientific rationale to implement epigenetically-based immunotherapies in cancer patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI